Supernus Pharmaceuticals, Inc. announced Intangible asset impairment charges for the quarter ended December 31, 2023. For the quarter, the company reported Intangible asset impairment charges of $20,189,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.51 USD | -0.94% | -5.46% | -4.94% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.94% | 1.51B | |
+16.17% | 79.16B | |
+8.63% | 8.72B | |
-16.43% | 4.79B | |
+48.34% | 4.62B | |
+2.91% | 3.82B | |
+14.51% | 2.33B | |
-26.94% | 2.2B | |
+16.55% | 2.1B | |
-36.25% | 2.04B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023